HPV-Cancer Targeting Immunotherapy Enters Phase 1 Clinical Trial After Showing Success In Animals

The paper highlights the candidate ’s ability to target and shrink HPV motivated tumors in both animal studies and human blood samples.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

Tumor lysis syndrome is uncommon in solid tumors but with the use of immunotherapy (checkpoint inhibitors) their incidence is increasing. Physicians need to take adequate precautions while treating patients with immunotherapy. The findings of our case report will help improve our current understanding of tumor lysis syndrome specially in solid tumors and will help in developing multidisciplinary treatment and prophylaxis strategies for this uncommon, but potentially fatal complication. AbstractTumor lysis syndrome is uncommon in solid tumors but with the use of immunotherapy (checkpoint inhibitors) their incidence is incre...
Source: Clinical Case Reports - Category: General Medicine Authors: Tags: CASE REPORT Source Type: research
Publication date: Available online 14 February 2020Source: Seminars in Cancer BiologyAuthor(s): Bhavika Gupta, Daizy Sadaria, Vaishnavi U. Warrier, Anuradha Kirtonia, Ravi Kant, Amit Awasthi, Prakash Baligar, Jayanta K. Pal, Eiji Yuba, Gautam Sethi, Manoj Garg, Rajesh Kumar GuptaAbstractPlant lectins, a natural source of glycans with a therapeutic potential may lead to the discovery of new targeted therapies. Glycans extracted from plant lectins are known to act as ligands for C-type lectin receptors (CLRs) that are primarily present on immune cells. Plant-derived glycosylated lectins offer diversity in their N-linked olig...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
It is widely assumed that immune checkpoint inhibition does not give rise to clinical benefits in patients with lung cancer and activating epidermal growth factor receptor (EGFR) mutations. Clinical trial data have predominantly demonstrated low activity of immunotherapy in this patient group, although some evidence has been obtained that implies outcome improvement with checkpoint inhibitors even in EGFR-positive disease. The case presented here demonstrates excellent activity of the PD-L1 inhibitor atezolizumab and the PD-1 inhibitor pembrolizumab as the sixth- and seventh-line treatments in a patient with EGFR-mutant me...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Case Reports Source Type: research
Pancreatic ductal adenocarcinoma (PDAC) is an incurable cancer resistant to traditional treatments, although a limited number of early-stage patients can undergo radical resection. Immunotherapies for the trea...
Source: Molecular Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Publication date: Available online 13 February 2020Source: CellAuthor(s): Yongchao Dou, Emily A. Kawaler, Daniel Cui Zhou, Marina A. Gritsenko, Chen Huang, Lili Blumenberg, Alla Karpova, Vladislav A. Petyuk, Sara R. Savage, Shankha Satpathy, Wenke Liu, Yige Wu, Chia-Feng Tsai, Bo Wen, Zhi Li, Song Cao, Jamie Moon, Zhiao Shi, MacIntosh Cornwell, Matthew A. WyczalkowskiSummaryWe undertook a comprehensive proteogenomic characterization of 95 prospectively collected endometrial carcinomas, comprising 83 endometrioid and 12 serous tumors. This analysis revealed possible new consequences of perturbations to the p53 and Wnt/&beta...
Source: Cell - Category: Cytology Source Type: research
AbstractTumor-associated macrophages (TAMs) are important regulators of the complex interplay between immune system and breast cancer. TAMs fuel the cancer progression and metastasis by reprogramming their specific functional phenotype in cancer settings. Therefore, it is important to clarify the mechanisms of shaping specific functional phenotype of macrophages in tumor milieu. LncRNA profiles of TAMs were identified by LncRNA microarray. Flow cytometry was used to detect the surface markers of TAMs. The co-localization among lincRNA-p21, p53 and Mouse Double Minute 2 (MDM2) was identified by FISH probe and immunofluoresc...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
ConclusionsSeveral TKIs are standard of care at different settings. Among those approved TKIs, tivozanib has similar efficacy than others with a better safety profile. The use of prognostic factors is critical to the selection of optimal therapy.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
Authors: Hoffmann TK PMID: 32047977 [PubMed - in process]
Source: HNO - Category: ENT & OMF Tags: HNO Source Type: research
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
After publication of the article [1], authors found out that Fig. 1 was inadvertently replaced.
Source: Molecular Cancer - Category: Cancer & Oncology Authors: Tags: Correction Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Immunotherapy | Pharmaceuticals | Study